TCGA-77-7138-01A-41R-2045-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.560
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.550
- MYC_TARGETS_V2+0.430
- UNFOLDED_PROTEIN_RESPONSE+0.370
- DNA_REPAIR+0.340
- TGF_BETA_SIGNALING+0.280
- OXIDATIVE_PHOSPHORYLATION+0.260
- MTORC1_SIGNALING+0.250
- MITOTIC_SPINDLE+0.220
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.310
- BILE_ACID_METABOLISM-0.300
- XENOBIOTIC_METABOLISM-0.280
- MYOGENESIS-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.260
- COAGULATION-0.250
- ADIPOGENESIS-0.220
- IL2_STAT5_SIGNALING-0.220
- KRAS_SIGNALING_DN-0.220
- WNT_BETA_CATENIN_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR15069617 | — | — | 0.848 |
| 2 | BS_R5SNFB5B | high-grade glioma | — | 0.844 |
| 3 | MNG979 | — | — | 0.842 |
| 4 | TCGA-91-6836-01A-21R-1858-07 | — | cohortA1 | 0.840 |
| 5 | MBCProject_1160_T2_RNA | — | E | 0.832 |
| 6 | 61F5C72A-4DDB-4EDB-908A-B2856CAFD8BD | — | — | 0.828 |
| 7 | TCGA-77-8144-01A-11R-2247-07 | — | cohortSQ1 | 0.821 |
| 8 | TCGA-DK-A3IM-01A-11R-A20F-07 | — | — | 0.820 |
| 9 | TCGA-P3-A6T2-01A-11R-A34R-07 | — | — | 0.818 |
| 10 | 78699d1d-aa39-473a-b3ea-24164d3a443c | — | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.190 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.120 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |